- Home
- NRO vs PBYI Comparison
NRO vs PBYI Comparison
Compare NRO & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- PBYI
- Stock Information
- Founded
- NRO 2003
- PBYI 2010
- Country
- NRO United States
- PBYI United States
- Employees
- NRO N/A
- PBYI N/A
- Industry
- NRO Finance/Investors Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- PBYI Health Care
- Exchange
- NRO Nasdaq
- PBYI Nasdaq
- Market Cap
- NRO 187.8M
- PBYI 153.2M
- IPO Year
- NRO N/A
- PBYI N/A
- Fundamental
- Price
- NRO $3.50
- PBYI $3.09
- Analyst Decision
- NRO
- PBYI Strong Buy
- Analyst Count
- NRO 0
- PBYI 1
- Target Price
- NRO N/A
- PBYI $7.00
- AVG Volume (30 Days)
- NRO 239.4K
- PBYI 754.5K
- Earning Date
- NRO 01-01-0001
- PBYI 02-27-2025
- Dividend Yield
- NRO 11.41%
- PBYI N/A
- EPS Growth
- NRO N/A
- PBYI 492.79
- EPS
- NRO N/A
- PBYI 0.47
- Revenue
- NRO N/A
- PBYI $243,569,000.00
- Revenue This Year
- NRO N/A
- PBYI N/A
- Revenue Next Year
- NRO N/A
- PBYI N/A
- P/E Ratio
- NRO N/A
- PBYI $6.63
- Revenue Growth
- NRO N/A
- PBYI 6.30
- 52 Week Low
- NRO $2.51
- PBYI $2.23
- 52 Week High
- NRO $3.45
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- NRO 42.49
- PBYI 49.17
- Support Level
- NRO $3.52
- PBYI $2.92
- Resistance Level
- NRO $3.62
- PBYI $4.06
- Average True Range (ATR)
- NRO 0.08
- PBYI 0.29
- MACD
- NRO 0.01
- PBYI 0.01
- Stochastic Oscillator
- NRO 40.00
- PBYI 27.07
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.